---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-133250"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:06:20.994325+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS acquires PXL-770 (SCY-770) from Poxel for $8M upfront, up to $188M total

## Summary
- Asset includes direct AMPK activator PXL-770, now SCY-770, for ADPKD, with Orphan Drug Designation from FDA.
- Upfront payment of $8M; potential development milestones up to $8M and commercial milestones up to $180M.
- Phase 2 proof-of-concept study in ADPKD expected to start Q4 2026; early efficacy readout anticipated H2 2027.
- SCY-770 has been evaluated in eight clinical trials with a favorable safety profile and targets underlying ADPKD drivers.
- SCYNEXIS plans to host a conference call on March 31, 2026 at 8:30 AM ET to discuss the acquisition and corporate update.

## SEC filing metadata
- accession: 0001193125-26-133250
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000119312526133250/0001193125-26-133250-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000119312526133250/d118823d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-133250
- JSON: https://secwatch.observer/filing/0001193125-26-133250.json
- Plain text: https://secwatch.observer/filing/0001193125-26-133250.txt

## Key facts
- Material Agreements
  SCYNEXIS INC entered into Asset Purchase Agreement with Poxel SA valued at $8,000,000 (effective 2026-03-30).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Poxel SA
  - Value: $8,000,000
  - Effective: 2026-03-30
  source text: On March 30, 2026, SCYNEXIS, Inc. (the “Company”) and Poxel SA, a French corporation (“Poxel”), entered into an asset purchase agreement (the “Asset Purchase Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178253/000119312526133250/0001193125-26-133250-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.